11月16日-18日，2024年美国心脏协会科学年会（2024 AHA）将在芝加哥以线下+线上结合的方式盛大召开。日前，大会议程已经公布，会议期间共设置了7个特色科学研究（Featured Science）专场，共29项研究，一起先睹为快吧！

作者：Xuemei Guo

FS.01 特色科学：血脂风险管理新方法 

1. LIBerate-OLE - Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial (LIBerate-OLE)

LIBerate-OLE开放标签扩展试验：在1468例心血管高危患者中，探究Lerodalcibep的长期疗效（72周）

2. LIBerate-HeFH_OLE - Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE)

LIBerate-HeFH_OLE开放标签扩展试验：在703例杂合子家族性高胆固醇血症患者中，探究第三代PCSK9抑制剂Lerodalcibep的疗效和安全性

3. PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)

PALISADE 3期试验：在急性胰腺炎（AP）高风险的遗传或临床定义的家族性乳糜小铁血症综合征（FCS）成人患者中，评估plzasiran的疗效和安全性

4. YELLOW III - Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study

YELLOW III试验：基于冠状动脉内斑块特征，在最大剂量他汀类药物治疗中加入依洛尤单抗的转录组特征和预测因素

FS.02 特色科学：健康技术与临床试验的未来 

1. DELIVER - Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER)

DELIVER试验：在全球临床试验中，使用自然语言处理来判断心衰住院情况

2. MAPS-LLM - Manual versus AI-Assisted Clinical Trial Screening using Large-Language Models (MAPS-LLM)

MAPS-LLM试验：人工 vs. 人工智能（大语言模型），来进行临床试验筛选

3. MyoMobile - Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care – A Randomized Parallel Group Trial (MyoMobile Study)

MyoMobile随机平行组试验：与标准护理相比，基于应用APP的个性化指导，可改善射血分数保留型心衰（HFpEF）患者的体力活动

4. mTECH-Rehab - Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial (mTECH-Rehab)

AHA健康技术网络mTECH-Rehab随机对照试验：基于家庭的技术支持的心脏康复对功能状态和心血管健康指标的影响

FS.03 特色科学：更接近峰值的新型HFpEF治疗方法 

1. Effect of finerenone on a hierarchical composite endpoint analyzed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF

FINEARTS-HF试验预先设定的分析：在射血分数轻度降低的心衰（HFmrEF）或HFpEF患者中，使用win统计法分析非奈利酮对分层复合终点事件的影响

2. Efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified sex-specific analysis of the FINEARTS-HF trial

FINEARTS-HF试验预先设定的性别特异性分析：在HFmrEF/ HFpEF患者中，探究非奈利酮的疗效和安全性

3. Finerenone and Risk of Hyperkalemia in Patients with Heart failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF)

FINEARTS-HF试验：在HFmrEF/ HFpEF患者中，探究非奈利酮应用与高钾血症风险之间的关系

4. Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial

来自SUMMIT试验的见解：替尔泊肽对HFpEF患者心肾终末器官损伤的影响

FS.04 特色科学：备受瞩目的血管治疗结果 

1. Geographical variations of treatment disparities between Black and White patients with peripheral artery disease across the United States

美国各地黑人和白人外周动脉疾病治疗的地域差异

2. Legend 1 - Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)

Legend 1随机、双盲、安慰剂对照试验：用于溃疡愈合的解剖导向下肢基因疗法

3. Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New insights from the CLEAR OUTCOMES Trial

来自CLEAR OUTCOMES试验的新见解：他汀类药物不耐受的外周动脉疾病患者，进行贝派地酸治疗的肢体结局

4. ONCO PE - Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial

ONCO PE试验：在肺栓塞风险低危的癌症患者，进行利伐沙班治疗的18个月和6个月结果对比

FS.05 特色科学：淀粉样变性、肥厚型心肌病和Danon型心肌病：靶向治疗和特定人群 

1. Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy (Accepted, not confirmed at time of publication)

RP-A501用于Danon病治疗的1期研究结果：RP-A501是治疗单基因心肌病的首个单剂量静脉注射基因疗法，其由血清型9重组腺相关病毒（AAV9）衣壳组成，包含一个功能性人源LAMP2B转基因（AAV9.LAMP2B）（已接受，发表时尚未确认）

2. VALOR-HCM - Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial

VALOR-HCM试验的128周结果：玛伐凯泰（Mavacamten）在因室间隔缩小术而转诊的阻塞性HCM患者中的疗效

3. Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

ATTRibute-CM开放标签扩展（OLE）研究的初步结果：Acoramidis可降低全因死亡率和心血管相关住院率

4. Impact of vutrisiran on markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

来自HELIOS-B试验的结果：vutrisiran对转甲状腺素蛋白淀粉样变性伴心肌病患者疾病进展标志物的影响

5. SCAN-MP - The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study (SCAN-MP)

SCAN-MP试验（少数民族人群核成像心脏淀粉样变性筛查试验）：转甲状腺素心脏淀粉样变性在老年黑人和西班牙裔心衰患者中的患病率

6. ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

ATTR特异性药物治疗在主动脉瓣狭窄和转甲状腺素心脏淀粉样变性双重病理患者中的疗效

FS.06 特色科学：心血管介入治疗结果新见解

1. Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial

SELECT试验：司美格鲁肽可改善既往进行冠脉搭桥手术的超重或肥胖患者的心血管预后

2. Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)

Amulet IDE随机对照试验5年结局：Amplatzer Amulet左心耳封堵器的疗效和安全性

3. The impact of carbon monoxide to determine the in-hospital prognosis after acute coronary syndrome (ADDICT-ICCU) - (Accepted, not confirmed at time of publication) 

ADDICT-ICCU试验：一氧化碳对急性冠状动脉综合征后院内预后的影响（已接受，发表时尚未确认）

4. Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement

二尖瓣环钙化严重程度的定量评估可预测接受经导管主动脉瓣置换术（TAVR）的重度主动脉瓣狭窄患者的预后

FS.07 特色科学：现在是制定内分泌调节相关护理标准的时候了

1. Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy

SUMMIT CMR子试验：在合并肥胖的HFpEF患者中，探究替尔泊肽对心脏结构和功能的影响

2. Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial

来自SUMMIT试验的结果：在射血分数保留型心衰患者中，探究替尔泊肽对临床和症状负担的影响

3. Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

来自FLOW试验的结果：司美格鲁肽对慢性肾脏病结局的益处

相关链接

2024 AHA热点聚焦：8个最新科学研究，3个最新基础科学研究专场，共69项最新研究结果即将揭晓~

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)